FAM102B

Across TCGA pan-cancer cohorts, FAM102B mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM102B data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FAM102B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM102B expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where FAM102B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.159	1.000	.001	25	view →
PDAC	OS	Tertile	III,IV	0.617	0.267	.011	14	view →
LSCC	OS	Median	II,III,IV	0.880	1.000	.015	4	view →
HNSC	OS	Median	All	0.904	0.783	.021	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM102B–CCRCC (DFS)

Open the CCRCC breakdown →